

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

ANNOUNCEMENT ON PARTICIPATION IN THE COLLECTIVE BRIEFING ON THE 2023 ANNUAL PERFORMANCE OF COMPANIES LISTED ON THE MAIN BOARD OF THE SHANGHAI STOCK EXCHANGE IN THE GREATER HEALTHCARE SECTOR AND BRIEFING ON THE FINANCIAL RESULTS FOR THE FIRST QUARTER OF THE FINANCIAL YEAR ENDING 31 DECEMBER 2024

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

IMPORTANT REMINDER

- **Subject of the briefing:** Collective Briefing on the 2023 Annual Performance of Companies Listed on the Main Board of the Shanghai Stock Exchange (“SSE”) in the Greater Healthcare Sector and Briefing on the Financial Results for the First Quarter of the Financial Year Ending 31 December 2024 (“1Q FY2024”)
- **Time of the briefing:** 4 June 2024 (Tuesday), from 1:30 p.m. to 4:30 p.m.
- **Venue/ Platform of the briefing:** SSE Roadshow Centre (上海证券交易所上证路演中心) (website: <https://roadshow.sseinfo.com/>)
- **Mode of the briefing:** video livestreaming and online text interaction
- **Submission of questions in advance:** Investors may submit questions via email to drt600329@163.com in advance of the briefing by 4:00 p.m. on Monday, 3 June 2024. The Company will address questions of general concern to investors at the briefing within the scope permitted for information disclosure.

The Company had announced its full year financial results for the financial year ended 31 December 2023 (“FY2023”) on 29 March 2024, and its financial results for 1Q FY2024 on 29 April 2024. The electronic copies of both announcements are available on SGXNET at <https://www.sgx.com/securities/company-announcements>. To facilitate a more comprehensive understanding of the Company’s operation results and financial status for FY2023 and 1Q FY2024, the Company will participate in the collective briefing on the 2023 annual performance of companies listed on the Main Board of the SSE in the greater healthcare sector. This briefing will be held on Tuesday, 4 June 2024 from 1:30 p.m. to 4:30 p.m..

1. Type of the briefing

The briefing will be conducted via video livestreaming and online text interaction. The Company will engage with investors to discuss the operating results and financial indicators for FY2023 and 1Q FY2024, and will address questions of general concern to investors within the scope permitted for

information disclosure.

2. Time and venue/ platform of the briefing

- (a) Time: 4 June 2024 (Tuesday), from 1:30 p.m. to 4:30 p.m.
- (b) Venue/ Platform: SSE Roadshow Centre (上海证券交易所上证路演中心) (website: <https://roadshow.sseinfo.com/>)
- (c) Mode: video livestreaming and online text interaction

3. Representatives of the Company

Ms. Wang Lei (Executive Director and General Manager), Mr. Liew Yoke Pheng Joseph (Independent and Non-Executive Director), Mr. Ma Jian (Chief Financial Officer) and Ms. Jiao Yan (Secretary to the Board) will attend the briefing for and on behalf of the Company. Attendance is subject to change in case of special circumstances.

4. Participation by investors

- (a) Investors can participate in the briefing by visiting the SSE Roadshow Centre (上海证券交易所上证路演中心) online at <https://roadshow.sseinfo.com/> to watch the live video broadcast of the briefing and interact with the Company via online text from 1:30 p.m. to 4:30 p.m. on Tuesday, 4 June 2024. The Company will endeavor to answer questions within the scope permitted for information disclosure and encourages active participation from all investors.
- (b) Investors may submit questions via email to drt600329@163.com in advance of the briefing by 4:00 p.m. on Monday, 3 June 2024. The Company will address questions of general concern to investors at the briefing within the scope permitted for information disclosure.

5. Contact information

Contact person: Wang Jian (王健), Jiang Ling (江凌)
Contact Number: (86) 022-27020892
Email address: drt600329@163.com

6. Other information

After the conclusion of the briefing, investors may review the convening details and main contents of the briefing through the SSE Roadshow Centre at <https://roadshow.sseinfo.com/>.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
27 May 2024